SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HUTCHMED Reports Orpathys Plus Tagrisso Reduced Progression or Death Risk in Phase III Study

HUTCHMED reported a reduced risk of disease progression or death with Orpathys plus Tagrisso in a Phase III study.

Related stories